Evidence indicates that certain genetic or genomic markers, such as PD-L1 expression (Taube et al., 2014), mismatch-repair status (Le et al., 2015), tumor mutational burden (Goodman et al., 2017), and tumor aneuploidy (Davoli et al., 2017; Li et al., 2019), are linked to cancer immunotherapy responses. This evidence concerns the gene CD274 and neoplasm.